The idea that proton therapy may be a safer alternative to radiotherapy for the asbestos-linked cancer malignant pleural mesothelioma is coming into question in light of recent research. A newly published study of proton therapy in patients with inoperable non-small cell lung cancer, a cancer with many similarities to mesothelioma, showed no difference between proton-based and standard photon-based radiotherapy in terms of lung toxicity or … Continue reading Proton Therapy for Mesothelioma: A Safer Radiation Treatment?
A new study on treatment disparities among lung cancer patients reflects a trend that has been documented among mesothelioma patients, as well; patients who are black or economically disadvantaged are less likely to get potentially life-saving treatments. Like non-small cell lung cancer, pleural mesothelioma affects the lungs. The standard of care is for patients to have a combination of chemotherapy and radiotherapy. For malignant mesothelioma … Continue reading Pleural Mesothelioma Treatment Disparities Seen in Lung Cancer Patients, Too
A team of Egyptian researchers is calling on mesothelioma doctors and patients to rethink their approach to treating this aggressive, asbestos-linked cancer. Scientists with Ain Shams University in Cairo conducted a review of studies on radical multi-modality approaches to malignant mesothelioma treatment and concluded that, despite what some other studies seem to suggest, this may not always be the best approach. What Are Radical Multi-Modal … Continue reading Radical Multi-Modal Mesothelioma Treatment: Is it Worth It?
Too many patients with malignant pleural mesothelioma are not getting the trimodality treatment protocol that could significantly change their outcomes. That is the finding of a newly-published study conducted at MD Anderson Cancer Center in Houston, Texas. Researchers reviewed the records of more than 20,000 patients in the National Cancer Database with a definitive diagnosis of pleural mesothelioma between 2004 and 2014. They discovered that, … Continue reading Many Pleural Mesothelioma Patients May Be Missing Out on Life-Extending Treatments
Treating malignant pleural mesothelioma patients with high doses of targeted radiotherapy after surgery or biopsy may significantly extend their lives. That’s the message from a multi-center mesothelioma study conducted in Italy and recently published in a French medical journal. Mesothelioma Treatment with Radiotherapy Scientists analyzed the cases of 36 malignant pleural mesothelioma patients diagnosed between 2009 and 2012. Nineteen of the patients were treated with … Continue reading High Dose Radiotherapy Improves Mesothelioma Survival in New Study
Researchers in California and Boston say blocking a process by which cells break down and recycle their components into new cells could make mesothelioma tumors more susceptible to chemotherapy. Although the process, known as autophagy, is a natural part of the lives of cells, it can also be induced by certain drugs. Emerging research suggests that the multi-stage process is not only more complex than … Continue reading Blocking This Cellular Process Could Help Mesothelioma Chemotherapy Work Better
Extrapleural pneumonectomy, the most radical – and risky – type of surgery for malignant pleural mesothelioma, is more likely to lead to long term survival when paired with strategic follow-up treatments. That is the conclusion of researchers at Japan’s Kyushu University who conducted a retrospective study of 10 mesothelioma patients who underwent EPP at their institution between 2001 to 2010. EPP Surgery and Mesothelioma Outcomes … Continue reading Radical Surgery Alone Unlikely to Prolong Mesothelioma Survival
Cancer researchers say the VEGF-inhibitor nintedanib (Ofev) extended mesothelioma survival by more than five months in patients on standard chemotherapy in a new trial. That is among the findings of a recently-published Phase II study of nintedanib as an adjunct therapy to pemetrexed (Alimta) and cisplatin for malignant pleural mesothelioma. Nintedanib Trial Details Nintedanib is currently used to treat idiopathic pulmonary fibrosis and some types … Continue reading New Chemotherapy Booster May Extend Mesothelioma Survival
A new study of mesothelioma treatment and survival in the US contains some disturbing facts about treatment trends. Among them is the fact that people over 70 are much less likely to get any treatment for malignant mesothelioma, a rare but but fast-growing malignancy that can be quickly fatal. In fact, nearly a third of mesothelioma patients receive no therapy at all. The study was … Continue reading New Report Reveals Disparities in Mesothelioma Treatment
Trimodality therapy including surgery, chemotherapy, and radiation appears to give carefully-selected patients the best odds of surviving mesothelioma. In a new article in the Journal of Clinical Oncology, researchers from MD Anderson Cancer Center detail the results of their analysis of mesothelioma survival using the National Cancer Database. Long-Term Mesothelioma Research The research team started with a pool of 20,561 pleural mesothelioma cases diagnosed between … Continue reading 10-Year Study Confirms Longer Mesothelioma Survival with Trimodal Therapy